Nicolas R Smoll1. 1. Gippsland Medical School, Monash University, Churchill, Victoria, Australia. nrsmoll@me.com
Abstract
BACKGROUND: Medulloblastomas are 1 of the most common brain tumors in children but can affect individuals of all ages. For this report, the author investigated the impact of medulloblastomas/primitive neuroectodermal tumors (PNETs) on the US population with a focus on age differences. METHODS: Data from the Surveillance, Epidemiology, and End Results (SEER) database were used to describe cumulative relative survival (CRS) using crude, period, and longitudinal period approaches for patients diagnosed with all medulloblastoma subtypes and PNETs. CRS estimates were obtained using SEER expected mortality data and the Ederer II method for expected survival estimation. These data were applied to the construction of rational follow-up scheduling protocols. RESULTS: The 5-year period CRS for all patients who were followed between 2001 and 2006 was 69%. Adults had a worse overall prognosis, but this difference in excess hazard rates appeared only after 4 years of follow-up. Furthermore, the 5-year and 10-year CRS has improved a minimum of 11% in children, adolescents, and adults over the past 25 years. CONCLUSIONS: The survival difference between children, adolescents, and adults with medulloblastomas and PNETs depended on the length of follow-up, which was described in this report as an age-by-follow-up interaction and observed as a "fork" on Kaplan-Meier curves. Differences in survival between children and adults emerged only 4 years after diagnosis, and adults fared worse. There has been significant improvement in survival from medulloblastomas/PNETs since the late 1970s and early 1980s.
BACKGROUND:Medulloblastomas are 1 of the most common brain tumors in children but can affect individuals of all ages. For this report, the author investigated the impact of medulloblastomas/primitive neuroectodermal tumors (PNETs) on the US population with a focus on age differences. METHODS: Data from the Surveillance, Epidemiology, and End Results (SEER) database were used to describe cumulative relative survival (CRS) using crude, period, and longitudinal period approaches for patients diagnosed with all medulloblastoma subtypes and PNETs. CRS estimates were obtained using SEER expected mortality data and the Ederer II method for expected survival estimation. These data were applied to the construction of rational follow-up scheduling protocols. RESULTS: The 5-year period CRS for all patients who were followed between 2001 and 2006 was 69%. Adults had a worse overall prognosis, but this difference in excess hazard rates appeared only after 4 years of follow-up. Furthermore, the 5-year and 10-year CRS has improved a minimum of 11% in children, adolescents, and adults over the past 25 years. CONCLUSIONS: The survival difference between children, adolescents, and adults with medulloblastomas and PNETs depended on the length of follow-up, which was described in this report as an age-by-follow-up interaction and observed as a "fork" on Kaplan-Meier curves. Differences in survival between children and adults emerged only 4 years after diagnosis, and adults fared worse. There has been significant improvement in survival from medulloblastomas/PNETs since the late 1970s and early 1980s.
Authors: Nicolas R Smoll; Oliver P Gautschi; Bawarjan Schatlo; Karl Schaller; Damien C Weber Journal: Neuro Oncol Date: 2012-07-06 Impact factor: 12.300
Authors: Yining Lu; Collin M Labak; Neha Jain; Ian J Purvis; Maheedhara R Guda; Sarah E Bach; Andrew J Tsung; Swapna Asuthkar; Kiran K Velpula Journal: Am J Cancer Res Date: 2017-03-01 Impact factor: 6.166
Authors: Paul L Moots; Anne O'Neill; Harold Londer; Minesh Mehta; Deborah T Blumenthal; Geoffrey R Barger; Margaret L Grunnet; Stuart Grossman; Mark R Gilbert; David Schiff Journal: Am J Clin Oncol Date: 2018-06 Impact factor: 2.339
Authors: Aaron P Brown; Christian L Barney; David R Grosshans; Mary Frances McAleer; John F de Groot; Vinay K Puduvalli; Susan L Tucker; Cody N Crawford; Meena Khan; Soumen Khatua; Mark R Gilbert; Paul D Brown; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-20 Impact factor: 7.038
Authors: Liguo Zhang; Xuelian He; Xuezhao Liu; Feng Zhang; L Frank Huang; Andrew S Potter; Lingli Xu; Wenhao Zhou; Tao Zheng; Zaili Luo; Kalen P Berry; Allison Pribnow; Stephanie M Smith; Christine Fuller; Blaise V Jones; Maryam Fouladi; Rachid Drissi; Zeng-Jie Yang; W Clay Gustafson; Marc Remke; Scott L Pomeroy; Emily J Girard; James M Olson; A Sorana Morrissy; Maria C Vladoiu; Jiao Zhang; Weidong Tian; Mei Xin; Michael D Taylor; S Steven Potter; Martine F Roussel; William A Weiss; Q Richard Lu Journal: Cancer Cell Date: 2019-08-29 Impact factor: 31.743
Authors: Donna L Johnston; Daniel Keene; Maria Kostova; Lucie Lafay-Cousin; Chris Fryer; Katrin Scheinemann; Anne-Sophie Carret; Adam Fleming; Vanessa Percy; Samina Afzal; Beverly Wilson; Lynette Bowes; Shayna Zelcer; Chris Mpofu; Mariana Silva; Valerie Larouche; Josee Brossard; Douglas Strother; Eric Bouffet Journal: J Neurooncol Date: 2015-05-30 Impact factor: 4.130
Authors: David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack Journal: Pediatr Blood Cancer Date: 2018-10-23 Impact factor: 3.167